Long non‑coding RNA‑CCAT2 promotes the occurrence of non‑small cell lung cancer by regulating the Wnt/β‑catenin signaling pathway

Abstract

The present study aimed to investigate the biological function of colon cancer-associated transcript 2 (CCAT2) in the occurrence and progression of non-small cell lung carcinoma (NSCLC) and its potential use in the early diagnosis and molecular-targeted therapy of NSCLC. The tumor tissues, para-carcinoma tissues and associated clinical data of 36 patients with NSCLC were collected in order to detect the expression of CCAT2 and assess the impact of factors including histopathological type, Tumor-Node-Metastasis stage and lymph node metastasis on CCAT2 expression. The lung cancer NCI-H1975 cell line was transfected with a small interfering RNA (siRNA) plasmid to determine the effect of si-CCAT2 on NSCLC proliferation, invasion and metastasis. The effect of si-CCAT2 on the expression of nuclear and cytoplasmic β-catenin protein in the lung cancer NCI-H1975 cell line was detected using western blot analysis. The expression levels of CCAT2 in the tumor tissues of patients with NSCLC were significantly higher than those in the normal para-carcinoma tissues (t=8.580, P<0.01). Subsequent to CCAT2 silencing, the proliferation and invasive abilities of NCI-H1975 cells were significantly decreased compared with control cells (P<0.05). In the si-CCAT2 group, the level of nuclear and cytoplasmic β-catenin proteins was decreased, and the activity of the Wnt signaling pathway was significantly inhibited compared with the control cells (P<0.01), and a synergistic effect was exerted with the Wnt signaling inhibitor FH535. CCAT2 may therefore promote the occurrence of NSCLC by regulating the Wnt/β-catenin signaling pathway.

Long non‑coding RNA CCAT2 promotes prostate cancer cell proliferation and invasion by regulating the Wnt/&beta;‑catenin signaling pathway

“…The role of lncRNAs in various biological processes, such as cell differentiation, proliferation and apoptosis in various diseases, including cancer, has received increasing attention (10)(11)(12). The colon cancer associated transcript 2 (CCAT2) gene has been reported to be upregulated in various types of human cancer, including gastric cancer, non-small cell lung cancer, esophageal cancer (13)(14)(15)(16)(17), hepatocellular carcinoma (18,19) and other tumors (20)(21)(22), and it is associated with the occurrence and metastasis of cancer, as well as poor prognosis. Previous studies have demonstrated that lncRNA CCAT2 is localized in the 8q24 genomic region, which has been identified as the first reproducible genetic risk site (23,24).…”

“…It has also been reported that by activating the Wnt/β-catenin signaling pathway, lncRNA CCAT2 affects oral squamous cell carcinoma, ovarian cancer and renal cell carcinoma (33), as well as non-small cell lung cancer, breast cancer, esophageal cancer and glioma (15,17,(33)(34)(35)(36)(37). However, to the best of our knowledge, no studies have previously examined the relationship between CCAT2 and the Wnt/β-catenin signaling pathway in PCa, and its potential regulatory mechanism.…”

Knockdown of long non‑coding RNA CCAT2 suppresses the progression of thyroid cancer by inhibiting the Wnt/β‑catenin pathway

“…CircRNA_102171 silencing suppresses the proliferation, migration and invasion of PTC cells and promotes apoptosis via regulating the Wnt/β-catenin pathway ( 35 ). The association between different lncRNAs and the Wnt/β-catenin signaling pathway in cancer cells is widely acknowledged ( 21 , 22 , 36 , 37 ). Zhao et al ( 21 ) found that CCAT2 could facilitate the occurrence of non-small lung cancer through activating the Wnt/β-catenin cascade.…”

“…The association between different lncRNAs and the Wnt/β-catenin signaling pathway in cancer cells is widely acknowledged ( 21 , 22 , 36 , 37 ). Zhao et al ( 21 ) found that CCAT2 could facilitate the occurrence of non-small lung cancer through activating the Wnt/β-catenin cascade. Ma et al ( 22 ) revealed that knocking down CCAT2 suppresses the malignancy of oral squamous cell carcinoma through inhibiting the Wnt pathway.…”

Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma

“…CCAT2 promoted the occurrence of NSCLC by regulating the Wnt/β-catenin signaling pathway. [35] Zhang et al found that CCAT2 was upregulated in ESCC tissues, especially in cases with lymph node metastasis (LNM), advanced TNM stages, and MYC amplification. Furthermore, the level of CCAT2 was positively correlated with TNM stages, LNM, and the number of positive lymph nodes, indicating CCAT2 might be a prognostic biomarker and therapeutic target for ESCC.…”